Lv11
40 积分 2023-12-21 加入
Opportunities and Challenges of Hepatic Impairment Physiologically Based Pharmacokinetic Modeling in Drug Development—An IQ Perspective
12小时前
待确认
Hepatic Impairment and the Differential Effects on Drug Clearance Mechanisms: Analysis of Pharmacokinetic Changes in Disease State
12小时前
待确认
Physiologically Based Pharmacokinetic Model‐Informed Drug Development for Polatuzumab Vedotin: Label for Drug‐Drug Interactions Without Dedicated Clinical Trials
22天前
已完结
Dose selection of novel anticancer drugs: exposing the gap between selected and required doses
29天前
已完结
Evaluating the drug-drug interactions of SHR4640 on repaglinide and midazolam in healthy subjects
1个月前
已完结
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
1个月前
已完结
Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor
1个月前
已完结
A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity
1个月前
已完结
A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity
1个月前
已完结
Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1
1个月前
已完结
皖公网安备34019202002308
